GELS_OUT_1 [2025-04-28 12:02:51 -0400] 3798 Bytes | 961 tokens | Cum: 961 tkns (12.01% of 8k)
==========================================================================

Alright, let’s light it up, because it's 12:02 PM on Mon Apr 28, 2025, and I'm charging into Gelteq (GELS), popping from $1.90 to $2.38. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Gelteq (GELS)
IPO: 2024-10-29 (6 Months Ago)
Market Cap: $8,494,268
Shares Outstanding: 9,440,000
Exchange: XNAS
Description: Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.

Here’s a list of headlines for Gelteq:

Feb-27-25 08:45AM - Gelteq's Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New Zealand
Feb-04-25 08:00AM - Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
Jan-24-25 08:00AM - Gelteq Appoints Matthew Jones as Head of Sports Performance
Dec-19-24 08:30AM - Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
Dec-17-24 08:30AM - Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
Dec-09-24 08:30AM - Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
Dec-02-24 08:30AM - Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
Nov-26-24 08:30AM - Gelteq Announces 400,000 Units Enter into Production in November 2024
Nov-12-24 09:00AM - Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
Oct-30-24 10:00AM - Gelteq Limited Closes US$5.2 Million Initial Public Offering
Oct-28-24 09:50PM - Gelteq Limited Prices US$5.2 Million Initial Public Offering

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-24T13:00:00Z - Gelteq Appoints Matthew Jones as Head of Sports Performance
B2 - 2024-10-30T14:00:00Z - Gelteq Limited Closes US$5.2 Million Initial Public Offering

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Gelteq (GELS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

GELS_OUT_3 [2025-04-28 12:02:51 -0400] 985 Bytes | 291 tokens | Cum: 1254 tkns (15.68% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T18:33:46Z - Top Biotech Stocks To Watch Today - April 22nd...
A2 - 2025-04-23T12:47:37Z - Enphase Energy Posts Downbeat Results, Joins Watsco And Other Big Stocks Moving Lower In Wednesday's...
A3 - 2025-04-23T12:06:43Z - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Forte Biosciences (NASDAQ:FBRX), En...
A4 - 2025-04-23T11:01:37Z - Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket - AgriFORC...
A5 - 2025-04-22T21:05:48Z - 12 Health Care Stocks Moving In Tuesday's After-Market Session - Akari Therapeutics (NASDAQ:AKTX), G...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GELS_OUT_5 [2025-04-28 12:02:52 -0400] 1182 Bytes | 293 tokens | Cum: 1549 tkns (19.36% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Top Biotech Stocks To Watch Today - April 22nd**Date: 2025-04-24Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/top-biotech-stocks-to-watch-today-april-22nd-2025-04-22/Danaher, Thermo Fisher Scientific, AbbVie, Medpace, Gelteq, Vertex Pharmaceuticals, and GSK are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that focus on biotechnology, which involves the use of living systems and organisms to develop products such as pharmaceuticals, diagnostics, and other health-related innovations. These stocks can be volatile due to high research and development costs, regulatory challenges, and the potential for breakthrough discoveries that may transform market values. These companies had the highest dollar trading volume of any Biotech s

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_7 [2025-04-28 12:02:53 -0400] 1182 Bytes | 249 tokens | Cum: 1800 tkns (22.50% of 8k)
==========================================================================

Showing A1 (chunk 2 of 11): tocks within the last several days.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR traded up $12.00 during midday trading on Tuesday, hitting $196.96.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_9 [2025-04-28 12:02:53 -0400] 1182 Bytes | 316 tokens | Cum: 2118 tkns (26.47% of 8k)
==========================================================================

Showing A1 (chunk 3 of 11): The stock had a trading volume of 3,502,407 shares, compared to its average volume of 4,493,179. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a market cap of $140.77 billion, a P/E ratio of 37.30, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The business has a fifty day moving average of $201.64 and a 200 day moving average of $226.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Read Our Latest Research Report on DHR

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and pr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_11 [2025-04-28 12:02:54 -0400] 1182 Bytes | 330 tokens | Cum: 2450 tkns (30.63% of 8k)
==========================================================================

Showing A1 (chunk 4 of 11): oduction of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE TMO traded up $13.92 during midday trading on Tuesday, hitting $435.77. 1,377,833 shares of the company traded hands, compared to its average volume of 2,123,162. Thermo Fisher Scientific has a 12-month low of $409.85 and a 12-month high of $627.88. The firm has a market cap of $164.50 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.99 and a beta of 0.86. The stock has a 50-day moving average price of $495.35 and a 200 day moving average price of $531.39. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Read Our Latest Research Report on TMO

AbbVie Inc. discovers, de

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_13 [2025-04-28 12:02:55 -0400] 1183 Bytes | 335 tokens | Cum: 2787 tkns (34.84% of 8k)
==========================================================================

Showing A1 (chunk 5 of 11): velops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

AbbVie stock traded up $3.64 on Tuesday, hitting $173.80. 1,709,588 shares of the stock traded hands, compared to its average volume of 7,097,494. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_15 [2025-04-28 12:02:56 -0400] 1182 Bytes | 289 tokens | Cum: 3078 tkns (38.48% of 8k)
==========================================================================

Showing A1 (chunk 6 of 11): of 17.94. The business's fifty day simple moving average is $198.01 and its 200 day simple moving average is $187.54. The firm has a market cap of $307.44 billion, a P/E ratio of 72.42, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55.

Read Our Latest Research Report on ABBV

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Medpace stock traded down $15.64 during mid-day trading on Tuesday, hitting $273.35. The company had a trading volume of 906,794 shares,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_17 [2025-04-28 12:02:57 -0400] 1182 Bytes | 302 tokens | Cum: 3382 tkns (42.27% of 8k)
==========================================================================

Showing A1 (chunk 7 of 11): compared to its average volume of 332,564. Medpace has a 12 month low of $250.84 and a 12 month high of $459.77. The stock's 50 day moving average price is $317.57 and its two-hundred day moving average price is $332.88. The company has a market capitalization of $8.26 billion, a PE ratio of 21.70, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46.

Read Our Latest Research Report on MEDP

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition.

GELS stock traded up $1.93 during midday trading on Tuesday, hitting $2.83. The company's stock had a trading volum

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_19 [2025-04-28 12:02:58 -0400] 1182 Bytes | 329 tokens | Cum: 3713 tkns (46.41% of 8k)
==========================================================================

Showing A1 (chunk 8 of 11): e of 75,947,508 shares, compared to its average volume of 1,151,343. The business has a 50-day simple moving average of $1.28. Gelteq has a 12 month low of $0.77 and a 12 month high of $5.50.

Read Our Latest Research Report on GELS

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ VRTX traded up $12.24 during trading hours on Tuesday, hitting $489.76. The company's stock had a trading volume of 298,434 shares, compared to its average volume of 1,325,754. The company has a debt-t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_21 [2025-04-28 12:02:59 -0400] 1182 Bytes | 318 tokens | Cum: 4033 tkns (50.41% of 8k)
==========================================================================

Showing A1 (chunk 9 of 11): o-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The company has a market cap of $125.77 billion, a P/E ratio of -222.86, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company's 50 day simple moving average is $487.25 and its two-hundred day simple moving average is $465.46. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88.

Read Our Latest Research Report on VRTX

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Shares of GSK traded up $0.40 during trading hours on Tuesday, hitting $36.85. The stock had a trading volume of 3,418,859 shares, compared to i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_23 [2025-04-28 12:03:00 -0400] 1183 Bytes | 314 tokens | Cum: 4349 tkns (54.36% of 8k)
==========================================================================

Showing A1 (chunk 10 of 11): ts average volume of 5,244,623. The firm has a market capitalization of $76.02 billion, a PE ratio of 23.17, a PEG ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a fifty day moving average price of $37.44 and a 200 day moving average price of $36.05. GSK has a 12 month low of $31.72 and a 12 month high of $45.92.

Read Our Latest Research Report on GSK

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GELS_OUT_25 [2025-04-28 12:03:01 -0400] 238 Bytes | 59 tokens | Cum: 4410 tkns (55.12% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GELS_OUT_27 [2025-04-28 12:03:01 -0400] 251 Bytes | 78 tokens | Cum: 4491 tkns (56.14% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

GELS_OUT_29 [2025-04-28 12:03:08 -0400] 4791 Bytes | 1158 tokens | Cum: 5652 tkns (70.65% of 8k)
==========================================================================

This is our set of metrics for Gelteq.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------+
| Volume: 285,497 | Perf Month: 112.53% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 1.52M | Perf Quarter: -14.89% | Short Float: 0.22% | ROE: - |
+--------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 0.49 | Index: - | Short Ratio: 0.01 | ROI: - |
+--------------------+-----------------------+------------------------+-------------------+
| RSI (14): 63.79 | Market Cap: 21.77M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.40 | Shs Outstand: 9.44M | Beta: - | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA20: 78.04% | Shs Float: 3.74M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA50: 67.16% | Inst Own: 0.86% | Sales past 5Y: -74.90% | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA200: 15.96% | Insider Own: 60.36% | Employees: 20 | |
+--------------------+-----------------------+------------------------+-------------------+
| Perf Week: 156.27% | Insider Trans: 0.00% | Debt/Eq: 0.25 | |
+--------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Gelteq officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.3813
Average Volume: 4725601.2
30-Day High: 2.88
30-Day Low: 0.82
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Gelteq (GELS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Gelteq.

2) MARKET_SCORE[]
This conversation was initiated because GELS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for GELS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, GELS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect GELS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Gelteq.

11) ETHICAL_RATING[]
Rate Gelteq’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Gelteq.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

GELS_IN_31 [2025-04-28 12:03:09 -0400] 126 Bytes | 29 tokens | Cum: 5882 tkns (73.52% of 8k)
==========================================================================

====================================
[2025-04-28 12:03:09] # Analysis Completed
Elapsed Time: 18.63 seconds